Company news

CSL Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy

September 26, 2025

VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment

September 16, 2025

CSL partners on new coagulation treatment

September 15, 2025

CSL FY25 Results and Major Strategic Initiatives

August 18, 2025

CSL Results Presentation

August 18, 2025

CSL Statutory Accounts for FY2025

August 18, 2025

Health Canada Has Authorized CSL's ANDEMBRY(R) (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

August 12, 2025

Health Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)

August 8, 2025

U.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start

June 16, 2025

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

May 23, 2025

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

April 29, 2025

CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)

February 20, 2025

CSL Statutory Accounts for the Half Year Ended 31 Dec 2024

February 10, 2025

Results Presentation

August 12, 2024

Results Announcement

August 12, 2024

Full Year Statutory Accounts for 30 June 2024

August 12, 2024

Half Year Results Investor Presentation

February 12, 2024

Statutory Accounts for the Half Year Ended 31 December 2023

February 12, 2024

Half Year Results Announcement

February 12, 2024

Top-line Results from the Phase 3 AEGIS-II Trial

February 11, 2024

CSL Results Announcement

August 14, 2023

CSL Statutory Accounts for the Full Year Ended 30 June 202

August 14, 2023

Market Update

June 13, 2023

CSL Statutory Accounts for the Half Year Ended 31 Dec 2022

February 13, 2023

CSL Half Year Results Announcement & Investor Presentation

February 13, 2023

Appointment of CSLs next CEO & Managing Director

December 12, 2022

CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology

October 31, 2022

CSL Vifor Market Briefing

October 16, 2022

Finalisation of Vifor Pharma Acquisition

August 1, 2022

Vifor update ASX Announcement for lodgement

May 11, 2022

CSL successfully issues bonds in US debt markets

April 20, 2022

Update on Acquisition of Vifor Pharma

March 3, 2022

Statutory Accounts for Half Year Ended 31 December 2021

February 15, 2022

CSL completes A$750 million Share Purchase Plan

February 13, 2022

Successful Completion of A$6.3B Institutional Placement

December 15, 2021

Investor Presentation CSL Swiss Tender Acquisition of Vifor

December 14, 2021

Swiss tender offer to acquire 100% of vifor pharma ltd

December 14, 2021

Trading Halt

December 13, 2021

CSL Statutory Accounts for the Full Year Ended 30 June 2021

August 17, 2021

Update on CSL Agreement with uniQure

May 6, 2021

Statutory Accounts for the Half Year Ended 31 Dec 2020

February 17, 2021

Dividend/Distribution - CSL

February 17, 2021

Update on UQ-CSL v451 COVID-19 Vaccine

December 10, 2020

Chairmans Address to Shareholders

October 13, 2020

CSL Supply Agreement for UQ Vaccine with Commonwealth

October 7, 2020

Statutory Accounts for the Full Year Ended 30 June 2020

August 18, 2020

CSL to acquire LateStage Gene Therapy Candidate from uniQure

June 24, 2020

Change in Leadership of CSLs Finance Function

June 16, 2020

New Debt Facilities to Strengthen Maturity Profile

May 6, 2020

CSL Statutory Accounts for the Half Year Ended 31/12/2019

February 11, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 82 decks. Every deck is listed under its year.